Core Viewpoint - Capricor Therapeutics, Inc. is facing a class action lawsuit due to allegations of misleading investors regarding its lead cell therapy candidate, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [1][2]. Summary by Relevant Sections Allegations - The complaint claims that Capricor provided investors with overly positive information about deramiocel's potential to obtain a Biologics License Application (BLA) from the FDA while concealing adverse facts about its safety and efficacy data from the Phase 2 HOPE-2 trial [1]. - On July 11, 2025, Capricor announced it received a Complete Response Letter (CRL) from the FDA, denying the BLA due to insufficient evidence of effectiveness and the need for additional clinical data [1]. Stock Price Impact - Following the announcement of the CRL, Capricor's stock price dropped from $11.40 per share on July 10, 2025, to $7.64 per share on July 11, 2025, reflecting a significant decline in investor confidence [1]. Class Action Details - Shareholders who purchased shares during the class period from October 9, 2024, to July 10, 2025, are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for September 15, 2025 [2]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case [2]. Law Firm's Mission - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices, seeking recovery for losses incurred due to misleading statements or omissions by companies [3].

Core Viewpoint - A class action lawsuit has been filed against Capricor Therapeutics, Inc. for allegedly providing misleading information regarding its lead drug candidate, deramiocel, during the class period from October 9, 2024, to July 10, 2025 [2][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Capricor securities during the specified class period [2]. - Investors have until September 15, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Allegations Against Capricor - The complaint alleges that Capricor provided materially misleading information about deramiocel's potential to obtain a Biologics License Application (BLA) from the FDA while concealing adverse facts regarding its safety and efficacy data from the Phase 2 HOPE-2 trial [4]. - On July 11, 2025, Capricor announced it received a Complete Response Letter (CRL) from the FDA, denying the BLA due to insufficient evidence of effectiveness and the need for additional clinical data [5]. Group 3: Stock Price Impact - Following the announcement of the CRL, Capricor's stock price fell from $11.40 per share on July 10, 2025, to $7.64 per share on July 11, 2025, reflecting a significant decline [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Capricor Therapeutics, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on September 15, 2025 [1] Group 1: Class Action Details - Investors who purchased Capricor securities between October 9, 2024, and July 10, 2025, may be entitled to compensation through a contingency fee arrangement [2] - A class action lawsuit has been filed, and interested parties must move the Court to serve as lead plaintiff by September 15, 2025 [3] - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4] Group 3: Case Specifics - The lawsuit alleges that Capricor provided misleading information regarding its lead drug candidate, deramiocel, while concealing adverse facts about its safety and efficacy data from a Phase 2 trial [5] - This misleading information allegedly led to shareholders purchasing securities at inflated prices, resulting in damages when the truth was revealed [5]

Core Viewpoint - Capricor Therapeutics, Inc. is under investigation by Faruqi & Faruqi, LLP for potential claims related to its operations and disclosures [1] Company Overview - Capricor Therapeutics, Inc. is listed on NASDAQ under the ticker symbol CAPR [1] - The company is being scrutinized by a prominent national securities law firm, which has a history of recovering significant amounts for investors [1] Legal Context - Faruqi & Faruqi, LLP has been active in securities law since 1995 and has offices in multiple states including New York, Pennsylvania, California, and Georgia [1] - The firm has successfully recovered hundreds of millions of dollars for investors, indicating a strong track record in handling similar cases [1]

Core Viewpoint - Capricor Therapeutics is addressing the FDA's Complete Response Letter (CRL) regarding its investigational cell therapy Deramiocel for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) and is committed to transparency and collaboration with the FDA to resolve outstanding issues [1][2][3] Company Overview - Capricor Therapeutics (NASDAQ: CAPR) is focused on developing cell and exosome-based therapeutics for rare diseases, with Deramiocel as its lead product candidate [7] - The company has received multiple designations for Deramiocel, including Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA [6] Product Details - Deramiocel (CAP-1002) is composed of allogeneic cardiosphere-derived cells (CDCs) that have shown immunomodulatory and anti-fibrotic effects in preserving cardiac and skeletal muscle function in DMD [5] - The therapy has been studied in over 250 peer-reviewed publications and administered to more than 250 human subjects in clinical trials [5] Regulatory Status - The FDA's CRL was received in July 2025, and Capricor plans to make its preliminary response to the FDA publicly available for transparency [2][3] - The company is awaiting official minutes from a recent Type A meeting with the FDA, which will help define the next steps in the regulatory process [3] Disease Context - Duchenne Muscular Dystrophy (DMD) is a severe genetic disorder affecting approximately 15,000 individuals in the U.S., primarily boys, leading to progressive muscle degeneration and heart failure [4]

NEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP reminds Capricor Therapeutics, Inc. ("Capricor†or the "Company†) (NASDAQ: CAPR) investors of the September 15, 2025 deadline to seek the role of lead plaintiff in a pending federal securities class action. If you purchased or otherwise acquired Capricor securities, have information, or would like to learn more, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the form below, to discuss your ri. ...

Core Viewpoint - Capricor Therapeutics, Inc. is facing a securities fraud class action lawsuit, with a deadline for investors to join the lawsuit approaching on September 15, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Southern District of California on behalf of investors who purchased or acquired Capricor securities between October 9, 2024, and July 10, 2025 [3]. - Allegations include misrepresentations regarding Capricor's four-year safety and efficacy data from the Phase 2 HOPE-2 trial study of deramiocel, the company's lead cell therapy candidate for treating cardiomyopathy associated with Duchenne muscular dystrophy [4]. Group 2: Investor Participation - Investors wishing to serve as lead plaintiffs must file necessary documents by September 15, 2025, although participation as a lead plaintiff is not required to share in any potential recovery [5]. - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [5]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented both individual investors and large public and private pension funds [6]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [6].

Core Viewpoint - Rosen Law Firm is urging investors of Capricor Therapeutics, Inc. to contact them regarding a class action lawsuit due to alleged misleading information about the company's business operations and its lead drug candidate, deramiocel [1][2][3]. Summary by Sections Allegations - The lawsuit claims that Capricor provided investors with misleading information about deramiocel, which is intended for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [3]. - Defendants allegedly made positive statements about obtaining a Biologics License Application (BLA) from the FDA while concealing adverse facts regarding the safety and efficacy data from the Phase 2 HOPE-2 trial [3]. Class Action Participation - Shareholders wishing to serve as lead plaintiffs must file motions by September 15, 2025, and can remain absent class members if they choose not to participate [4]. - The law firm operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is won [5]. About Rosen Law Firm - Rosen Law Firm is recognized for its leadership in shareholder rights litigation and has recovered over $1 billion for shareholders since its inception [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Capricor Therapeutics, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on September 15, 2025 [1] Group 1: Class Action Details - Investors who purchased Capricor securities between October 9, 2024, and July 10, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by September 15, 2025 [3] - The lawsuit alleges that Capricor provided misleading information regarding its lead drug candidate, deramiocel, which led to artificially inflated stock prices [5] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise in this area [4]

Core Viewpoint - Capricor Therapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to its lead cell therapy candidate, deramiocel, which is intended for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [1][2] Group 1: Lawsuit Details - The lawsuit seeks to recover losses for investors affected by alleged fraud between October 9, 2024, and July 10, 2025 [1] - Defendants allegedly provided misleading information regarding Capricor's ability to obtain a Biologics License Application (BLA) from the FDA for deramiocel while concealing adverse facts about its Phase 2 HOPE-2 trial data [2] - Following the announcement of a Complete Response Letter (CRL) from the FDA on July 11, 2025, which denied the BLA due to insufficient evidence of effectiveness, Capricor's stock price fell from $11.40 to $7.64 per share [2] Group 2: Next Steps for Investors - Investors who suffered losses during the relevant period have until September 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4]